MX2020003114A - Tratamiento de deposicion anormal de grasa visceral utilizando polipeptidos de receptor 3 de factor de crecimiento de fibroblastos soluble (sfgfr3). - Google Patents

Tratamiento de deposicion anormal de grasa visceral utilizando polipeptidos de receptor 3 de factor de crecimiento de fibroblastos soluble (sfgfr3).

Info

Publication number
MX2020003114A
MX2020003114A MX2020003114A MX2020003114A MX2020003114A MX 2020003114 A MX2020003114 A MX 2020003114A MX 2020003114 A MX2020003114 A MX 2020003114A MX 2020003114 A MX2020003114 A MX 2020003114A MX 2020003114 A MX2020003114 A MX 2020003114A
Authority
MX
Mexico
Prior art keywords
visceral fat
sfgfr3
polypeptides
fat deposition
treatment
Prior art date
Application number
MX2020003114A
Other languages
English (en)
Spanish (es)
Inventor
Elvire Gouze
Stéphanie Garcia
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2020003114A publication Critical patent/MX2020003114A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2020003114A 2017-09-20 2018-09-20 Tratamiento de deposicion anormal de grasa visceral utilizando polipeptidos de receptor 3 de factor de crecimiento de fibroblastos soluble (sfgfr3). MX2020003114A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762561140P 2017-09-20 2017-09-20
PCT/EP2018/075471 WO2019057820A1 (en) 2017-09-20 2018-09-20 ABNORMAL VISCERAL GREASE DEPOSITION TREATMENT USING SOLUBLE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (SFGFR3) POLYPEPTIDES

Publications (1)

Publication Number Publication Date
MX2020003114A true MX2020003114A (es) 2020-10-20

Family

ID=63878625

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003114A MX2020003114A (es) 2017-09-20 2018-09-20 Tratamiento de deposicion anormal de grasa visceral utilizando polipeptidos de receptor 3 de factor de crecimiento de fibroblastos soluble (sfgfr3).

Country Status (12)

Country Link
US (1) US20200297799A1 (OSRAM)
EP (1) EP3684394A1 (OSRAM)
JP (1) JP7335247B2 (OSRAM)
KR (1) KR20200103621A (OSRAM)
CN (1) CN111836634A (OSRAM)
AU (1) AU2018335837A1 (OSRAM)
BR (1) BR112020005459A2 (OSRAM)
CA (1) CA3076396A1 (OSRAM)
IL (1) IL273203A (OSRAM)
MX (1) MX2020003114A (OSRAM)
PH (1) PH12020550461A1 (OSRAM)
WO (1) WO2019057820A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160002681A (ko) 2013-01-16 2016-01-08 인썸(인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르) 골격 성장 지연 질환의 예방 또는 치료에 사용하기 위한 용해성 섬유아세포 성장 인자 수용체 3(fgr3) 폴리펩티드
HUE058734T2 (hu) 2016-07-07 2022-09-28 Pfizer Szolúbilis 3-as fibroblaszt növekedési faktor receptor (sFGFR3) polipeptidek és alkalmazásaik
NL2020176B1 (en) * 2017-12-22 2019-07-02 Van Der Hoeven Horticultural Projects B V Greenhouse
CN110272900B (zh) * 2019-04-19 2024-03-26 中国人民解放军陆军军医大学 用于制备骨骼发育异常猪模型的sgRNA及其应用
WO2022106976A1 (en) 2020-11-18 2022-05-27 Pfizer Inc. Stable pharmaceutical formulations of soluble fgfr3 decoys
WO2022254319A1 (en) 2021-06-01 2022-12-08 Pfizer Inc. Cell culture method for producing sfgfr3 polypeptide
KR20240109587A (ko) * 2023-01-03 2024-07-11 서울대학교산학협력단 Fgfr3 발현 또는 활성 억제제의 퇴행성 신경질환 치료 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002235202A1 (en) * 2000-12-18 2002-07-01 Gene Logic, Inc. Treatment of bone disorders by modulation of fgfr3
KR20160002681A (ko) * 2013-01-16 2016-01-08 인썸(인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르) 골격 성장 지연 질환의 예방 또는 치료에 사용하기 위한 용해성 섬유아세포 성장 인자 수용체 3(fgr3) 폴리펩티드
SI3097122T1 (sl) * 2014-01-24 2020-07-31 Ngm Biopharmaceuticals, Inc. Protitelesa, ki se vežejo v domeni beta klotho 2, in metode za njihovo uporabo
ES2843637T3 (es) 2015-01-07 2021-07-19 Pfizer Señuelos FGFR3 solubles para tratar trastornos del crecimiento esquelético
HUE058734T2 (hu) * 2016-07-07 2022-09-28 Pfizer Szolúbilis 3-as fibroblaszt növekedési faktor receptor (sFGFR3) polipeptidek és alkalmazásaik

Also Published As

Publication number Publication date
JP2020534367A (ja) 2020-11-26
KR20200103621A (ko) 2020-09-02
IL273203A (en) 2020-04-30
CA3076396A1 (en) 2019-03-28
BR112020005459A2 (pt) 2020-09-29
CN111836634A (zh) 2020-10-27
AU2018335837A1 (en) 2020-04-23
RU2020113712A3 (OSRAM) 2022-01-14
RU2020113712A (ru) 2021-10-20
PH12020550461A1 (en) 2021-03-22
WO2019057820A1 (en) 2019-03-28
US20200297799A1 (en) 2020-09-24
JP7335247B2 (ja) 2023-08-29
EP3684394A1 (en) 2020-07-29

Similar Documents

Publication Publication Date Title
PH12020550461A1 (en) Treatment of abnormal visceral fat deposition using soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides
ZA201903327B (en) Compositions and methods for the induction of cd8+ t¿cells
SG11202104501UA (en) Systems and methods for the treatment of eye conditions
SG10201809457YA (en) Insulin receptor partial agonists
MX2020001774A (es) Composiciones y métodos para tratar enfermedad colestásica.
HUE072288T2 (hu) Aprocitentán további hatóanyagokkal való kombinációi rezisztens magas vérnyomás kezelésére
MY208231A (en) Mavacamten for use in the treatment of hypertrophic cardiomyopathy
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
ZA202006610B (en) Compositions for the treatment of skin conditions
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
MX2017010150A (es) Bacterias probioticas recombinantes.
ZA202007055B (en) Compositions for the treatment of skin conditions
PH12020550255A1 (en) Treatment of smc mediated disease
PH12019501534A1 (en) Csf1r-based chimeric proteins
MX2018003536A (es) Metodos para el tratamiento de la epilepsia.
PH12021550122A1 (en) Solubilized apyrases, methods and use
IL275349A (en) Use of hM4Di in the treatment of seizure disorders
SG11202010948XA (en) Use for preventing and treating myeloid-derived suppressor cell-related diseases
IL274838A (en) Use of MIR101 or MIR128 in the treatment of seizure disorders
ZA202105101B (en) Peptides for treatment and prevention of diabetes and associated disorders
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
MX2020003575A (es) Nuevos derivados de alcoxiamino para tratar dolor y estados relacionados con dolor.
IL282059A (en) Abexitide for the treatment of hyperinsulinemic hypoglycemia
NZ747201A (en) (+)-azasetron for use in the treatment of ear disorders
WO2016179103A8 (en) Pink1 c-terminal domain polypeptide and methods using the same in cancer treatment